Advances in lncRNAs from stem cell-derived exosome for the treatment of cardiovascular diseases.
Advances in lncRNAs from stem cell-derived exosome for the treatment of cardiovascular diseases.
复制标题
干细胞来源的外泌体lncRNA用于治疗心血管疾病的进展
DOI：
10.3389/fphar.2022.986683
复制
发表时间：
2022
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
心血管疾病（CVD）是全球死亡率的主要原因。从早期诊断和精确医学的优势中受益，基于干细胞的疗法已成为CVD的有前途的治疗选择。但是，自体或同种异体干细胞移植施加了免疫排斥，输注毒性和肿瘤发生的潜在风险。幸运的是，外泌体可以覆盖这些限制。越来越多的证据表明，来自干细胞旁分泌因子的外泌体的长期非编码RNA（LNCRNA）在干细胞疗法中起着关键作用，并参与了许多调节过程，包括转录沉默，转录激活，染色体修饰，染色体修饰和核内运输。因此，LNCRNA可以通过直接作用于特定的信号通路来治疗CVD。这项迷你综述系统地总结了不同干细胞中LNCRNA对心肌衰老和凋亡，缺血 - 再灌注损伤，视网膜病变，动脉粥样硬化和高血压的关键调节作用。此外，讨论了LNCRNA治疗CVD的当前挑战和未来的前景。
Cardiovascular diseases (CVDs) are the leading cause of mortality globally. Benefiting from the advantages of early diagnosis and precision medicine, stem cell-based therapies have emerged as promising treatment options for CVDs. However, autologous or allogeneic stem cell transplantation imposes a potential risk of immunological rejection, infusion toxicity, and oncogenesis. Fortunately, exosome can override these limitations. Increasing evidence has demonstrated that long non-coding RNAs (lncRNAs) in exosome from stem cell paracrine factors play critical roles in stem cell therapy and participate in numerous regulatory processes, including transcriptional silencing, transcriptional activation, chromosome modification, and intranuclear transport. Accordingly, lncRNAs can treat CVDs by directly acting on specific signaling pathways. This mini review systematically summarizes the key regulatory actions of lncRNAs from different stem cells on myocardial aging and apoptosis, ischemia-reperfusion injury, retinopathy, atherosclerosis, and hypertension. In addition, the current challenges and future prospects of lncRNAs treatment for CVDs are discussed.